Anti-Venom Market Revenue Opportunies 2026 Estimated By Global Key Players Haffkine Bio-Pharmaceutical Corporation Ltd., Bharat Serums and Vaccines Ltd, Vins Bioproducts Limited, CSL Behring, Vacsera, Rare Therapeutics, Incepta Vaccine Ltd.

Anti-venom is a medication majorly used to treat snake bites and it can also be used to treat bites from scorpions, spiders or other reptiles. It is made by fractionating the blood of the donor (horse or sheep), which is hyperimmunized with snake venom. These products are available in either lyophilized or liquid forms. Anti-venom is the only effective therapy against snake bites and apart from lifesaving, they also save patients from cell and tissue necrosis, thus helping save vital organs. As per World Health Organization (WHO) fact sheet, 4.5 to 5.4 million people are bitten by snakes, every year, globally, out of which 1.8 to 2.7 million people develop clinical illnesses after snake bites and up to 81,000 to 1, 38,000 people die from such snake bites. Snakebite causes around 400,000 amputations and other permanent disabilities, annually.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1249

South Asia and Africa are expected to drive growth of the anti-venom market, owing to higher incidence of snakebites

Growth of the anti-venom market is expected to be driven by South Asia and sub-Saharan African countries due to highest incidence of snake bites in these regions. As per WHO statistics, in India, 3.8 million people are bitten by snakes and 46,900 people die every year. In sub-Saharan Africa, around 7,000 to 20,000 people die annually from snake bites. Highest incidence is recorded in rural and peri-urban areas, where croppers and livestock workers live. However, growing urbanization is resulting in the loss of habitat for many snake species due to deforestation, thus drawing them towards area inhabited by humans, in turn, increasing the incidence of snakebites. The WHO, in June 2017, added snakebite to its priority list of neglected tropical disease, which would result in more focused effort to prevent death from snakebite, thus boosting growth of the anti-venom market. Increasing government funding for research and development and logistics in these countries is further drive growth of the global anti-venom market. Anti-venom product requires specialized infrastructure such as cold chain storage, which is not available adequately in highly prone regions such as Africa and Asia. This in turn, is hindering the supply of anti-venom products in these regions.

Key Players Present In The Anti-Venom Market:

Haffkine Bio-Pharmaceutical Corporation Ltd., Bharat Serums and Vaccines Ltd, Vins Bioproducts Limited, CSL Behring, Vacsera, Rare Therapeutics, Instituto Bioclon S.A.de C.V., and Incepta Vaccine Ltd.

Market Segmentation of the Global Anti-venom Market:

On The Basis Of Anti-Venom Type:

• Monovalent (Hyper immunizing venom obtained from single species)
• Polyvalent (Hyper immunizing venom from two or more species)

On The Basis Of Product Type:

• Snake anti-venom
• Scorpion anti-venom
• Spider anti-venom
• Other anti-venom products

On The Basis Of Distribution Channel:

• Hospitals
• Private clinics
• Ambulatory surgical centers

On The Basis Of Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1249

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.